Researchers at the Henry Ford Health System in Southeast Michigan have found that early administration of the drug hydroxychloroquine makes hospitalized patients substantially less likely to die.
The study, published in the International Journal of Infectious Diseases, determined that hydroxychloroquine provided a "66% hazard ratio reduction," and hydroxychloroquine and azithromycin a 71 percent reduction, compared to neither treatment.
In-hospital mortality was 18.1 percent with both drugs, 13.5 percent with just hydroxychloroquine, 22.4 percent with azithromycin alone, and 26.4 percent with neither drug. "Prospective trials are needed" for further review, the researchers note.
"Our results do differ from some other studies," Dr. Marcus Zervos, who heads the hospital's infectious diseases unit, said at a news conference. "What we think was important in ours ... is that patients were treated early. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with COVID."
 |
A statement from the Trump campaign hailed the study as "fantastic news."
"Fortunately, the Trump Administration secured a massive supply of hydroxychloroquine for the national stockpile months ago," a statement read. "Yet this is the same drug that the media and the Biden campaign spent weeks trying to discredit and spread fear and doubt around because President Trump dared to mention it as a potential treatment for coronavirus."
It added: "The new study from the Henry Ford Health System should be a clear message to the media and the Democrats: stop the bizarre attempts to discredit hydroxychloroquine to satisfy your own anti-Trump agenda. It may be costing lives."Read the rest of the story HERE and follow links below to related stories and resources:
Trump administration launching new pandemic response unit
USA TODAY: Coronavirus Updates
WSJ: Coronavirus Live Updates
YAHOO NEWS: Coronavirus Live Updates
NEW YORK POST: Coronavirus The Latest
If you like what you see, please "Like" us on Facebook either here or here. Please follow us on Twitter here.
No comments:
Post a Comment